Professor Sir David Lane is now listed as one of Phylogica's ongoing academic research partners. What brings the discoverer of P53 and one of the world's most eminent cancer scientists into our orbit?
P53, the Guardian of the Genome is faulty or inactivated in the majority of cancers. Is it possible that targeting mutated P53 and Myc is a potential and powerful therapeutic opportunity?
There is research paper on the Dual targeting of P53 and c-Myc in leukaemic stem cells published in the June 2016 edition of Nature. Could leukaemia be a target or possibly is the target more likely to be triple negative breast cancer? Treatments for TNBC is one of the most urgent needs in breast cancer therapeutics. It is also listed as a potential targeted indication under the Myc program on Phylogica's website.
PYC Price at posting:
3.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)